{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:46:32Z","timestamp":1790815592783,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":548,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.exphem.2024.104179","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T11:30:01Z","timestamp":1707478201000},"page":"104179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Antileukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome"],"prefix":"10.1016","volume":"132","author":[{"given":"Tatsuhiko","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Kanezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Toki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0623-8082","authenticated-orcid":false,"given":"Ryo","family":"Okuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1606-7328","authenticated-orcid":false,"given":"Akie","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kamio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-8635","authenticated-orcid":false,"given":"Kiminori","family":"Terui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0168-2475","authenticated-orcid":false,"given":"Etsuro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2024.104179_bib0001","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2024.104179_bib0002","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(03)13266-7","article-title":"Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder","volume":"361","author":"Groet","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2024.104179_bib0003","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2002-12-3904","article-title":"Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis","volume":"101","author":"Mundschau","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0004","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1182\/blood-2003-01-0013","article-title":"GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome","volume":"101","author":"Hitzler","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0005","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2002-11-3599","article-title":"Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21","volume":"102","author":"Rainis","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0006","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2003-02-0390","article-title":"Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0007","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1182\/blood-2010-05-282426","article-title":"Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia","volume":"116","author":"Kanezaki","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0008","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1182\/blood-2011-03-342774","article-title":"Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia","volume":"118","author":"Alford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0009","doi-asserted-by":"crossref","first-page":"eabf6202","DOI":"10.1126\/science.abf6202","article-title":"Mapping the cellular origin and early evolution of leukemia in Down syndrome","volume":"373","author":"Wagenblast","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.exphem.2024.104179_bib0010","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/ng.2759","article-title":"The landscape of somatic mutations in Down syndrome-related myeloid disorders","volume":"45","author":"Yoshida","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2024.104179_bib0011","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2024.104179_bib0012","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1200\/JCO.2007.12.3687","article-title":"Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group","volume":"25","author":"Kudo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2024.104179_bib0013","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/pbc.25789","article-title":"Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: a nationwide prospective study in Japan","volume":"63","author":"Taga","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.exphem.2024.104179_bib0014","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2017-01-764324","article-title":"Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial","volume":"129","author":"Taub","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0015","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2021012206","article-title":"High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial","volume":"138","author":"Hitzler","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0016","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1038\/s41375-021-01414-y","article-title":"Clinical and biological aspects of myeloid leukemia in Down syndrome","volume":"35","author":"Boucher","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2024.104179_bib0017","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2013.02.017","article-title":"Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome","volume":"19","author":"Hitzler","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2024.104179_bib0018","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2012-03-414755","article-title":"Clinical characteristics and outcome of refractory\/relapsed myeloid leukemia in children with Down syndrome","volume":"120","author":"Taga","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0019","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2024.104179_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0021","doi-asserted-by":"crossref","first-page":"e27414","DOI":"10.1002\/pbc.27414","article-title":"Effective response to azacitidine in a child with a second relapse of myeloid leukemia associated with Down syndrome after bone marrow transplantation","volume":"65","author":"Uemura","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.exphem.2024.104179_bib0022","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41588-023-01399-7","article-title":"Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model","volume":"55","author":"Waugh","year":"2023","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2024.104179_bib0023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.exphem.2024.104179_bib0024","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.exphem.2024.104179_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13046-017-0493-5","article-title":"Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells","volume":"36","author":"Bista","year":"2017","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.exphem.2024.104179_bib0026","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2024.104179_bib0027","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283437","article-title":"Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase","author":"Jeyaraju","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2024.104179_bib0028","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2024.104179_bib0029","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.1813666116","article-title":"Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome","volume":"116","author":"Leung","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2024.104179_bib0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2141.1995.tb05591.x","article-title":"Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome","volume":"90","author":"Ito","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2024.104179_bib0031","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/leu.2011.207","article-title":"CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors","volume":"26","author":"Negrotto","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2024.104179_bib0032","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Erratum: inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"152","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2024.104179_bib0033","doi-asserted-by":"crossref","first-page":"e16220","DOI":"10.7554\/eLife.16220","article-title":"Trisomy 21 consistently activates the interferon response","volume":"5","author":"Sullivan","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.exphem.2024.104179_bib0034","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10875-020-00803-9","article-title":"Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome","volume":"40","author":"Kong","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.exphem.2024.104179_bib0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.coi.2021.06.006","article-title":"Down syndrome and type I interferon: not so simple","volume":"72","author":"Malle","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.exphem.2024.104179_bib0036","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.immuni.2022.09.007","article-title":"Excessive negative regulation of type I interferon disrupts viral control in individuals with Down syndrome","volume":"55","author":"Malle","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.exphem.2024.104179_bib0037","first-page":"1393","article-title":"Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin","volume":"94","author":"Taub","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0038","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.stem.2015.07.007","article-title":"Inflammation-induced emergency megakaryopoiesis driven by hematopoietic stem cell-like megakaryocyte progenitors","volume":"17","author":"Haas","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2024.104179_bib0039","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2013-10-531038","article-title":"Posttranscriptional regulation of c-Myc expression in adult murine HSCs during homeostasis and interferon-\u03b1-induced stress response","volume":"123","author":"Ehninger","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2024.104179_bib0040","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.tim.2017.01.001","article-title":"Transcriptional regulation of antiviral interferon-stimulated genes","volume":"25","author":"Wang","year":"2017","journal-title":"Trends Microbiol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X24000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:39:09Z","timestamp":1759567149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X24000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":40,"alternative-id":["S0301472X24000389"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104179","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antileukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2024.104179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104179"}}